Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
08:00pm, Wednesday, 03'rd Sep 2025
BEIJING--(BUSINESS WIRE)-- #AntibodyDrugDiscovery--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
11:11am, Wednesday, 03'rd Sep 2025
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
12:57pm, Tuesday, 02'nd Sep 2025
"Dogs of the Dow" is a classic investment strategy. The idea is to find top-tier companies whose stocks are trading at unusually low prices, presumably for temporary reasons.
Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
08:00am, Tuesday, 02'nd Sep 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for i
Merck's cholesterol drug meets main goal in late-stage trial
07:09am, Tuesday, 02'nd Sep 2025
Drugmaker Merck's oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesday, marking a second win for the drug since June.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3.
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
06:30am, Tuesday, 02'nd Sep 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.
Top 10 High-Yield Dividend Stocks For September 2025
10:35pm, Sunday, 31'st Aug 2025
My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
02:45am, Saturday, 30'th Aug 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
11:21am, Friday, 29'th Aug 2025
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Merck: Buy the Next Dip Despite Short-Term Pressures
01:17pm, Thursday, 28'th Aug 2025
Merck's Q2 2025 results highlight strong growth in Keytruda and Animal Health, while its bullish chart pattern and low valuation make it a compelling long-term buy.
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 28'th Aug 2025
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
12:16pm, Thursday, 28'th Aug 2025
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
10:26am, Thursday, 28'th Aug 2025
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
